Now offering adenovirus and lentivirus production services! Learn More
Transfer of Services from Penn Vector Core to Franklin Biolabs
Certain AAV research vector production services previously provided by the Penn Vector Core are now available via Franklin Biolabs.
The Gene Therapy Program (GTP) at the University of Pennsylvania (Penn) transitioned its activities to Franklin Biolabs on October 1, 2024. 1
Certain vector manufacturing capabilities previously provided by the Penn Vector Core of the Gene Therapy Program at the University of Pennsylvania have been acquired by Franklin Biolabs, and such services are now available via Franklin Biolabs.
The Team You Trust, Now at Franklin Biolabs
Franklin Biolabs is a genetic medicines-focused contract research organization (CRO) founded by gene therapy pioneer James Wilson, MD, PhD. Over the past few decades, the Franklin Biolabs team has played a pivotal role in shaping the field of genetic medicines. They have led the way in advancements in AAV-based therapies within academic and industry settings. Based in Philadelphia and recognized as a global leader in genetic medicine innovation, our dedicated experts have supported both industry and academic research, leveraging key service centers to accelerate breakthroughs from discovery to the clinic.
Looking to Place an Order?
Place your research-grade AAV vector order today and accelerate your preclinical studies with reliable, high-quality production you can trust.
Order Here
Franklin Biolabs’ Vector, CMC and Analytical Services
We provide full-service AAV vector production for genetic medicine, supporting all stages from discovery to clinical trials with scalable, tailored solutions.
AAV vector manufacturing is a critical first step in the development of many gene therapies. It involves designing, characterizing, and optimizing plasmids, manufacturing the vectors at the appropriate scale, and analyzing the final product.
Our research-grade AAV vectors play an essential role in a variety of preclinical applications, both in vitro and in vivo, providing the foundational tools needed to advance genetic medicines toward clinical development.
Our deep expertise and unique insights into product-specific behavior enable process development that supports robust and effective platform technologies.
With cutting-edge process technologies such as high-density suspension or adherent-based culture and novel analytics available, we can accelerate the development of your advanced therapy program from discovery through commercialization.
Large-scale vector manufacturing process is a crucial step in the development of many gene therapies, scaling up the production of vectors that have shown promising effects in early studies.
Building on the foundation established at the research-scale stage, our large-scale manufacturing provides sufficient vector material to support more extensive preclinical investigations. This includes generating the critical data needed to meet the regulatory requirements set by agencies worldwide.
Analytical testing services are crucial for the successful development of gene therapies. Complete characterization of both the drug product and drug substance from preclinical through clinical stages is essential for understanding biological effects and meeting the criteria set by regulatory bodies worldwide.
The evolving field of analytical testing leverages cutting-edge technologies that we deploy to ensure our products consistently meet the highest quality and safety standards.
AAV vector manufacturing is a critical first step in the development of many gene therapies. It involves designing, characterizing, and optimizing plasmids, manufacturing the vectors at the appropriate scale, and analyzing the final product.
Our research-grade AAV vectors play an essential role in a variety of preclinical applications, both in vitro and in vivo, providing the foundational tools needed to advance genetic medicines toward clinical development.
Our deep expertise and unique insights into product-specific behavior enable process development that supports robust and effective platform technologies.
With cutting-edge process technologies such as high-density suspension or adherent-based culture and novel analytics available, we can accelerate the development of your advanced therapy program from discovery through commercialization.
Large-scale vector manufacturing process is a crucial step in the development of many gene therapies, scaling up the production of vectors that have shown promising effects in early studies.
Building on the foundation established at the research-scale stage, our large-scale manufacturing provides sufficient vector material to support more extensive preclinical investigations. This includes generating the critical data needed to meet the regulatory requirements set by agencies worldwide.
Analytical testing services are crucial for the successful development of gene therapies. Complete characterization of both the drug product and drug substance from preclinical through clinical stages is essential for understanding biological effects and meeting the criteria set by regulatory bodies worldwide.
The evolving field of analytical testing leverages cutting-edge technologies that we deploy to ensure our products consistently meet the highest quality and safety standards.
Want to Talk to a Member of the Team?
To get in touch with Kenton Woodard and the rest of the Franklin Biolabs’ team, please fill the form on our Contact Us page.
Learn More